Solubilization and Wetting Effects of Bile Salts on the Dissolution of Steroids
Sodium taurocholate increases steroid dissolution rates primarily through wetting effects for most steroids, though solubility becomes dominant for more lipophilic compounds at higher concentrations.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This paper investigated how sodium taurocholate affects the initial dissolution rate of five steroids by comparing contributions from solubility, wetting, and changes in diffusion coefficient, using bile salt concentrations corresponding to fasted and fed physiological states. The authors found that wetting effects predominated over solubilization for hydrocortisone, triamcinolone, betamethasone, and dexamethasone at both fasted and higher fed-state concentrations, with bile salt–mediated solubilization of about twofold or less and negligible diffusivity changes up to 30 mM. For the more lipophilic danazol, wetting effects were only notable at premicellar bile salt levels, whereas at higher concentrations increased solubility dominated, with micelles producing a slight diffusivity decrease at ≥15 mM. The study’s main limitation is that it focuses on in vitro dissolution/physicochemical mechanisms for these steroid compounds rather than biological outcomes. This paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Full text
7,445 characters
· extracted from
oa-doi-fallback
· 2 sections
· click to expand
Abstract
References
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (37)
- doi:10.1002/jps.2600570809 via openalex
- W45488122 via openalex
- doi:10.1002/jps.2600540503 via openalex
- doi:10.1080/00365521.1977.12031121 via openalex
- doi:10.1016/0378-5173(81)90070-3 via openalex
- doi:10.1016/0378-5173(82)90128-4 via openalex
- doi:10.1002/jps.2600770409 via openalex
- doi:10.1002/jps.2600731210 via openalex
- doi:10.1002/jps.2600741109 via openalex
- doi:10.1021/ja02086a003 via openalex
- doi:10.1007/978-1-4615-7969-4_2 via openalex
- doi:10.1002/jps.2600550906 via openalex
- W2406892203 via openalex
- W2442803527 via openalex
- W4290244548 via openalex
- doi:10.1002/jps.2600650805 via openalex
- doi:10.1002/jps.2600541119 via openalex
- doi:10.1016/0032-5910(69)80105-1 via openalex
- doi:10.1002/jps.2600611113 via openalex
- doi:10.1111/j.1748-1716.1959.tb01763.x via openalex
- doi:10.1016/0021-9797(82)90335-6 via openalex
- doi:10.1002/jps.2600561005 via openalex
- doi:10.1002/jps.2600760909 via openalex
- doi:10.1016/0378-5173(82)90175-2 via openalex
- doi:10.1073/pnas.71.10.3917 via openalex
- doi:10.1016/0378-5173(86)90148-1 via openalex
- doi:10.1002/jps.2600590206 via openalex
- doi:10.1248/cpb.27.2468 via openalex
- doi:10.1016/0378-5173(80)90086-1 via openalex
- doi:10.1002/jps.2600750723 via openalex
- doi:10.1002/jps.2600550213 via openalex
- doi:10.1002/jps.2600710921 via openalex
- doi:10.1248/cpb.26.2832 via openalex
- doi:10.1016/0016-5085(80)90244-9 via openalex
- doi:10.1016/0009-8981(86)90044-6 via openalex
- doi:10.1002/jps.2600581115 via openalex
- doi:10.1080/00365521.1974.12096876 via openalex
Cited by (22)
- Exploring the Impact of Intestinal Fluid Components on the Solubility and Supersaturation of Danazol 2021
- Role of wetting agents and disintegrants in development of danazol nanocrystalline tablets 2020
- Danazol oral absorption modelling in the fasted dog: An example of mechanistic understanding of formulation effects on drug pharmacokinetics 2019
- An in Vitro Digestion Test That Reflects Rat Intestinal Conditions To Probe the Importance of Formulation Digestion vs First Pass Metabolism in Danazol Bioavailability from Lipid Based Formulations 2014
- Application of Capmul MCM and caprylic acid for the development of danazol-loaded SEDDS 2014
- Non-linear Increases in Danazol Exposure with Dose in Older vs. Younger Beagle Dogs: The Potential Role of Differences in Bile Salt Concentration, Thermodynamic Activity, and Formulation Digestion 2014
- Luminal Lipid Phases after Administration of a Triglyceride Solution of Danazol in the Fed State and Their Contribution to the Flux of Danazol Across Caco-2 Cell Monolayers 2012
- Incomplete Desorption of Liquid Excipients Reduces the <i>in Vitro</i> and <i>in Vivo</i> Performance of Self-Emulsifying Drug Delivery Systems Solidified by Adsorption onto an Inorganic Mesoporous Carrier 2012
- Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis 2008
- Increasing the Proportional Content of Surfactant (Cremophor EL) Relative to Lipid in Self-emulsifying Lipid-based Formulations of Danazol Reduces Oral Bioavailability in Beagle Dogs 2007
- Evaluation of the Impact of Surfactant Digestion on the Bioavailability of Danazol after Oral Administration of Lipidic Self-Emulsifying Formulations to Dogs 2007
- Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug 2005
- In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media 2005
- Rapid Dissolution of High‐Potency Danazol Particles Produced by Evaporative Precipitation into Aqueous Solution 2004
- Improvement of Dissolution Rates of Poorly Water Soluble APIs Using Novel Spray Freezing into Liquid Technology 2002
- A dynamic in vitro lipolysis model 2001
- A Comparison of the Solubility of Danazol in Human and Simulated Gastrointestinal Fluids 2000
- Surface treatment of the hydrophobic drug danazol to improve drug dissolution 1998
- A Study of the Complexation Between Danazol and Hydrophilic Cyclodextrin Derivatives 1996
- Bioavailability of danazol-hydroxypropyl-β-cylodextrin complex by different routes of administration 1996
- Characterization and bioavailability of danazol-hydroxypropyl β-cyclodextrin coprecipitates 1996
- Absorption of Danazol After Administration to Different Sites of the Gastrointestinal Tract and the Relationship to Single‐ and Double‐Peak Phenomena in the Plasma Profiles 1993
Source provenance
- openalex
- last seen: 2026-05-11T06:16:32.963054+00:00